Abstract: The present disclosure provides mTOR agonists that selectively modulate proteasome dynamics, compositions, methods and uses thereof for modulation of stress-induced proteasome dynamics and related pathological conditions. The present disclosure specifically provides therapeutic methods for treating disorders associated with cytosolic accumulation of the proteasome. The invention further provides prognostic methods for detection and monitoring drug resistant cancers, as well as methods for screening for modulators of proteasome dynamics.

Abstract: Methods, systems, and apparatuses are provided for inferring security incidents from observational data. For example, alerts generated with respect to a set of entities by a first alert generator are received, association scores are calculated for pairs of alerts, the alerts are formed into clusters based on the association scores, and a security incident model is formed based on the clusters. The security incident model may define sequences of alerts corresponding to security incidents. Furthermore, the security incident model may be used to determine a match between additional alerts and a sequence of alerts in the security incident model and identify the additional alerts as a security incident corresponding to the sequence of alerts in the security incident model.

Abstract: The present invention is directed to a monoclonal antibody or an antigen-binding portion thereof having specific binding affinity to RING finger protein 4 (RNF4). The invention is further directed to use of the antibody or an antigen-binding portion thereof in detecting a RNF4-associated disease in a subject, such as cancer.

Abstract: Methods, systems, and apparatuses are provided for inferring security incidents from observational data. For example, alerts generated with respect to a set of entities by a first alert generator are received, association scores are calculated for pairs of alerts, the alerts are formed into clusters based on the association scores, and a security incident model is formed based on the clusters. The security incident model may define sequences of alerts corresponding to security incidents. Furthermore, the security incident model may be used to determine a match between additional alerts and a sequence of alerts in the security incident model and identify the additional alerts as a security incident corresponding to the sequence of alerts in the security incident model.

Abstract: The present invention is directed to a monoclonal antibody or an antigen-binding portion thereof having specific binding affinity to RING finger protein 4 (RNF4). The invention is further directed to use of the antibody or an antigen-binding portion thereof in detecting a RNF4-associated disease in a subject, such as cancer.

Abstract: Methods, systems, and media are shown for creating and deploying honey tokens for intrusion detection in a remote computing resource system. Resource modules provisioned for a tenant are identified for intrusion detection. For each identified resource modules, a provisioned resource having a corresponding access credential is allocated and the access credential is deployed in the identified resource module. A data entry is created in a token mapping store that identifies the access credential and the resource module. Access logs are scanned to detect access attempts. For each access attempt, the token mapping store is searched for a data entry with an access credential that matches the access credential of the access attempt. If found, an alert is generated that includes the identified resource module of the matching data entry.

Abstract: A method of treating multiple sclerosis (MS) in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of an isolated polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein said antigen recognition domain comprises CDR amino acid sequences as set forth in SEQ ID NO: 11, 15, 19, 23, 27 and 31, thereby treating MS in the subject.

Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.

Abstract: A method of treating multiple sclerosis (MS) in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of an isolated polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein said antigen recognition domain comprises CDR amino acid sequences as set forth in SEQ ID NO: 11, 15, 19, 23, 27 and 31, thereby treating MS in the subject.

Abstract: A method of treating a graft rejection disease in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of an isolated polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein said antigen recognition domain comprises CDR amino acid sequences as set forth in SEQ ID NO: 11, 15, 19, 23, 27 and 31, thereby treating the graft rejection disease in the subject.

Abstract: A method of treating a graft rejection disease in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of an isolated polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein said antigen recognition domain comprises CDR amino acid sequences as set forth in SEQ ID NO: 11, 15, 19, 23, 27 and 31, thereby treating the graft rejection disease in the subject.

Abstract: An isolated polypeptide is provided. The polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein the antigen recognition domain comprises at least three CDR amino acid sequences selected from the group consisting of SEQ ID NO: 11, 15, 19, 23, 27 and 31. Also provided are compositions which comprise the peptide and uses of same.

Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.

Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.

Abstract: An isolated polypeptide is provided. The polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein the antigen recognition domain comprises at least three CDR amino acid sequences selected from the group consisting of SEQ ID NO: 11, 15, 19, 23, 27 and 31. Also provided are compositions which comprise the peptide and uses of same.

Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.

Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.

Abstract: An isolated polypeptide is provided. The polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein the antigen recognition domain comprises at least three CDR amino acid sequences selected from the group consisting of SEQ ID NO: 11, 15, 19, 23, 27 and 31. Also provided are compositions which comprise the peptide and uses of same.

Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.

Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.